Abstract 4366623: Metabolomics of Right Ventricular Systolic Function Across the Spectrum of Pulmonary Hypertension – insights from the PVDOMICS Cohort

J Jonah Garry (Vanderbilt Univ Medical Center, Nashville, Tennessee, United States) S Samuel Chung (NYP-Weill Cornell, New York City, New York, United States) J Jonathan Chacon-Barahona (NYP-Weill Cornell, New York City, New York, United States) R Robert Frantz (MAYO CLINIC, Rochester, Minnesota, United States) F Franz Rischard (Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, AZ (F.R.).) C Catherine Simpson P Paul Hassoun (Johns Hopkins University, Baltimore, Maryland, United States) S Stephen Mathai (Johns Hopkins University, Baltimore, Maryland, United States) J Jan Krumsiek A Alexandra Racanelli (NYP-Weill Cornell, New York City, New York, United States) E Evan Brittain (Vanderbilt University Medical Cente, Nashville, Tennessee, United States) A Anna Hemnes (VANDERBILT UNIVERSITY, Nashville, Tennessee, United States) E Evelyn Horn (Perkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, NY (E.H.).)

Abstract

Introduction: PH increases RV afterload, often leading to RV systolic and diastolic failure. The metabolic mechanisms underlying RV dysfunction remain poorly understood and are largely unexplored across non-PAH forms of PH. Aims: We aimed to identify which metabolites and metabolic pathways associated with imaging measures of RV systolic function. Methods: We analyzed data from the multi-center PVDOMICS cohort, which includes echo, CMR, invasive hemodynamics, clinical phenotyping, and untargeted plasma metabolomics (via Metabolon). RV systolic function metrics selected as the outcome measures for this study were fractional area change (echo), global longitudinal strain (echo), and RVEF (CMR). Associations between non-xenobiotic, named metabolites and RV function measures were assessed using linear regression adjusted for age, sex, BMI, and PH group, with significance defined by FDR <0.05. Metabolite set enrichment analysis (MSEA) was performed to identify significantly enriched pathways (FDR <0.20). To complement MSEA, we conducted mean-aggregation analysis: we averaged metabolite concentrations within each pathway and tested associations with RV function using the same covariate adjustments (FDR <0.05). Results: We identified 979 participants with plasma metabolomics and at least one available outcome measure (317 Group 1 PH; 106 Group 2 PH; 140 Group 3 PH; 51 Group 4 PH; 26 Group 5 PH; 81 Healthy Controls; 258 Disease Comparators). Linear regression identified 170 metabolites from the 647 named metabolites significantly associated with all 3 RV metrics (Top 10 by average ranked p-value displayed in Image 1 ). MSEA revealed seven enriched pathways across all RV metrics: Androgenic Steroids, Pregnenolone Steroids, Progestin Steroids, Fatty Acid Metabolism (Acyl Choline), Histidine metabolism, Vitamin A metabolism, Gamma-glutamyl Amino Acid ( Image 2) . Mean aggregation analysis showed that higher concentrations of Androgenic/Pregnenolone Steroids and Vitamin A metabolites strongly associated with improved RV function, while higher levels of Fatty Acid Metabolism (Acyl Carnitine) and Acetylated Peptides associated with worse function ( Image 3 ). Conclusions: Using data from the multi-institutional PVDOMICS cohort, we provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Steroid hormones as well as Vitamin A and fatty acid metabolites emerged as central to RV systolic function.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

J

Jonah Garry

Vanderbilt Univ Medical Center, Nashville, Tennessee, United States

S

Samuel Chung

NYP-Weill Cornell, New York City, New York, United States

J

Jonathan Chacon-Barahona

NYP-Weill Cornell, New York City, New York, United States

R

Robert Frantz

MAYO CLINIC, Rochester, Minnesota, United States

F

Franz Rischard

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, AZ (F.R.).

C

Catherine Simpson

P

Paul Hassoun

Johns Hopkins University, Baltimore, Maryland, United States

S

Stephen Mathai

Johns Hopkins University, Baltimore, Maryland, United States

J

Jan Krumsiek

A

Alexandra Racanelli

NYP-Weill Cornell, New York City, New York, United States

E

Evan Brittain

Vanderbilt University Medical Cente, Nashville, Tennessee, United States

A

Anna Hemnes

VANDERBILT UNIVERSITY, Nashville, Tennessee, United States

E

Evelyn Horn

Perkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, NY (E.H.).